Adrenergics Flashcards
Inhibitor: Tyrosine Hydroxylase
Catalyzes Tyrosine –> DOPA metabolism
RATE-LIMITING STEP
Metyrosine
Inhibitor: VMAT
Blocks H+/dopamine countertransport
Vesicular Monoamine Transporter (VMAT)
Reserpine
Inhibitor: Vesicle release
Inhibits VAMP/SNAP interaction + NE/ATP/P release
Bretylium
Guanethidine
Inhibitor: NET
Norepinephrine Transporter (NET)
Cocaine, Tricyclic Antidepressants (TCAs)
Chatecholamines (3)
- ) Dopamine
- ) Norepinephrine
- ) Epinephrine
Indolamines (2)
- ) Serotonin (5-HT)
2. ) Melatonin
Reserpine
Inhibitor of VMAT transport
-depletes secretory vesicles of NTs
-prevents release into synapses
S/Sx: MAJOR depressive disorder (“no joy”)
MAO (MOA + 2 Classes)
Monoamine Oxidase -converts amine --> acid (inactivates) -associated with mitochondria (intracellular) MAO-A --> 5-HT + NE MAO-B --> dopamine (DA)
COMT
Catechol-O-methyltransferase
- methylates hydroxyl group (ring)
- POST-synaptic membrane + cytosol
- primarily extracellular**
Alpha-1 Receptors
Vascular SM
Fx: vasoconstriction
Alpha-2 Receptors
Brain
Fx: lowers blood pressure
“reduce sympathetic output”
Beta-1 Receptors
Heart
Fx: increased contraction force, increase HR
Beta-2 Receptors
Bronchial SM + Vascular SM
Fx: Dilation (both areas)
Beta-3 Receptors
Adipose tissue
Fx: lipolysis
VERY RARE
Beta-Adrenergic Receptors: GCPR Effect
Increase/stimulate Adenylate Cyclase (AC)
Increased [cAMP]
Alpha-Adrenergic Receptors: Adenylate Cyclase (AC)
Decreased/inhibits Adenylate Cyclase (AC)
Decreased [cAMP]
Uses of Adrenergic Agonists
Cardiovascular (Shock, anaphylaxis, HTN)
Respiratory (COPD, asthma)
Ophthalmic (glaucoma, dilation)
CNS (ADHD, narcolepsy, pain, depression)
NorEpi Therapy Problems (4)
- ) Non-selective (a1, a2, b1, b2)
- ) Rapid metabolism (COMT + MAO)
- ) Poor oral bioavailability
- ) Does not cross BBB
NorEpi Alterations: Amino Substitution
Increases b-receptor affinity
-prevents MAO-A metabolism (blocks amino group)
NorEpi Alteration: OH modification
Inhibits COMT-metabolism
- increases oral bioavailability
- increased duration of action
- increases BBB penetration/permeability
Epinephrine (modifications, receptor affinity)
Methyl group added to NorEpi NH2 (blocks MAO)
a1 = a2 = b1 ≈ b2
Isoproterenol (modifications, receptor affinity)
Isopropyl group conjugated to NorEpi NH2
b1 = b2»_space;»»>a1/2
Affinity to b receptors increases as group conjugated to amine increases in size (CH3 vs. CH(CH3)2)
Adrenergic Agonist Effects: a1
a1 –> peripheral blood vessel SM (vasoconstriction)
Increased BP, peripheral resistance
Non-CV: decongestant, pupil dilation (phenylephrine)
NO EFFECT ON ACCOMMODATION
Adrenergic Agonist Effects: a2
a2 –> post-synaptic receptors brain
Reduced sympathetic outflow, decreased BP
Non-CV: decongestant, glaucoma (brimonidine)